Literature DB >> 27787743

Respiratory chain inhibition: one more feature to propose MPTP intoxication as a Leigh syndrome model.

Barbara Da Costa1,2, Elodie Dumon1,2, Laurence Le Moigno3, Sylvie Bodard3, Pierre Castelnau3, Thierry Letellier2, Christophe Rocher4,5.   

Abstract

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxicated mice have been widely used to model the loss of dopaminergic neurons. As this treatment leads to basal ganglia degeneration, it was proposed that MPTP mice could be used as a model of Leigh syndrome. However, this mitochondrial pathology is biochemically characterized by a respiratory chain dysfunction. To determine if MPTP can affect in vivo mitochondria function, we measured the activities of mitochondrial respiratory chain complexes in several tissues. Our results show that MPTP affects mainly mitochondrial respiratory chain complex IV, as found in Leigh Syndrome, confirming that acute MPTP intoxicated mice are a good model of Leigh Syndrome.

Entities:  

Keywords:  MPTP; Mice model; Mitochondrial diseases; Respiratory chain

Mesh:

Substances:

Year:  2016        PMID: 27787743     DOI: 10.1007/s10863-016-9683-7

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  24 in total

1.  Tissue variation in the control of oxidative phosphorylation: implication for mitochondrial diseases.

Authors:  R Rossignol; T Letellier; M Malgat; C Rocher; J P Mazat
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

Review 2.  Mitochondrial respiratory-chain diseases.

Authors:  Salvatore DiMauro; Eric A Schon
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

3.  Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis.

Authors:  F Medja; S Allouche; P Frachon; C Jardel; M Malgat; B Mousson de Camaret; A Slama; J Lunardi; J P Mazat; A Lombès
Journal:  Mitochondrion       Date:  2009-05-09       Impact factor: 4.160

4.  Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.

Authors:  Joanna A Korecka; Ruben Eggers; Dick F Swaab; Koen Bossers; Joost Verhaagen
Journal:  Restor Neurol Neurosci       Date:  2013       Impact factor: 2.406

Review 5.  The MPTP model of Parkinson's disease.

Authors:  Richard Jay Smeyne; Vernice Jackson-Lewis
Journal:  Brain Res Mol Brain Res       Date:  2005-03-24

Review 6.  Leigh syndrome: Resolving the clinical and genetic heterogeneity paves the way for treatment options.

Authors:  Mike Gerards; Suzanne C E H Sallevelt; Hubert J M Smeets
Journal:  Mol Genet Metab       Date:  2015-12-19       Impact factor: 4.797

7.  Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptine.

Authors:  M Battino; G P Littarru; A Gorini; R F Villa
Journal:  Neurochem Res       Date:  1996-12       Impact factor: 3.996

8.  MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood.

Authors:  E Lagrue; B Abert; L Nadal; L Tabone; S Bodard; F Medja; A Lombes; S Chalon; P Castelnau
Journal:  Metab Brain Dis       Date:  2009-03-25       Impact factor: 3.584

9.  Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+.

Authors:  B R Ransom; D M Kunis; I Irwin; J W Langston
Journal:  Neurosci Lett       Date:  1987-04-10       Impact factor: 3.046

10.  Leigh syndrome: clinical features and biochemical and DNA abnormalities.

Authors:  S Rahman; R B Blok; H H Dahl; D M Danks; D M Kirby; C W Chow; J Christodoulou; D R Thorburn
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.